At Pharmidex , we are proud to offer a comprehensive preclinical platform for autoimmune disease research. Using in vivo EAE models, we combine: ✔️ Bioanalysis & biomarker profiling to quantify key cytokines and mediators of disease progression ✔️ Histological assessment, enabling detailed evaluation of inflammation, demyelination and tissue pathology across multiple organs ✔️ Pharmacological intervention studies, including established treatments such as Fingolimod for validation This integrated approach delivers a complete and translationally relevant dataset, supporting drug discovery and development programmes from mechanistic insight through to therapeutic evaluation. By combining in vivo efficacy, biomarker analysis and histology, our team provides partners with a more comprehensive understanding of disease mechanisms and treatment effects. 👉 Learn more about our services in Histology, Biomarker Analysis, and Autoimmune Disease Models.

We’re delighted to share that Martin Barrett , our Head of Business Development, and Rob Jenkins , our Bioanalytical Scientist, will be attending the 51st Open Meeting 2025. This event is a fantastic opportunity to connect with industry leaders, share insights and build new collaborations. Martin and Rob are looking forward to meeting fellow attendees, exchanging ideas and exploring ways to create impactful partnerships that advance drug discovery and development. 🤝 If you’re attending, don’t hesitate to reach out they’ll be happy to connect, discuss your projects, and explore potential synergies.